08:00 , Jan 27, 2014 |  BC Week In Review  |  Clinical News

MatriStem MicroMatrix: Phase IV started

ACell began a single-blind, U.S. Phase IV trial to compare standard of care (SOC) plus MatriStem MicroMatrix particles or MatriStem Wound Matrix sheets vs. SOC plus Dermagraft in about 102 patients with diabetic foot...
07:00 , Mar 30, 2009 |  BC Week In Review  |  Company News

ACell, Medline Industries Inc. sales and marketing update

Medline received exclusive, North American rights to market and distribute sheet formulations of ACell's MatriStem wound care matrix for management of partial- and full-thickness wounds, including diabetic, venous, arterial and pressure ulcers, as well as...